Following the successful conclusion of the 37th IPVC in Bangkok, Thailand, the global HPV research community is now looking ahead to the next major gathering. The 38th International Papillomavirus Conference (IPVC 2026) will be held in Athens, Greece, from October 22 to 25, 2026.
Hosted by the International Papillomavirus Society (IPVS), IPVC 2026 will bring together experts from around the world in basic science, clinical medicine, epidemiology, and public health to exchange the latest advances in HPV research. The scientific program will cover papillomavirus molecular biology, virus–host interactions, diagnosis and treatment of HPV-related diseases, vaccines and therapeutic strategies, epidemiology, disease prevention and control, and implementation science. New findings will be presented through plenary sessions, symposia, oral presentations, and poster sessions.
As a leading international scientific conference in the HPV field, IPVC 2026 will provide an important platform for scientific exchange, clinical translation, and international collaboration, further advancing HPV research and the prevention and control of HPV-related diseases.
The REBACIN® R&D team will attend IPVC 2026 and present its research, “REBACIN® for Persistent High-Risk HPV Infection: Mechanistic Insights, Localized Sustained Delivery, and Real-World Clinical Outcomes.” The presentation will share recent research progress on REBACIN® for persistent high-risk HPV infection and provide an opportunity to exchange scientific perspectives with international researchers on emerging concepts, technologies, and therapeutic strategies in the HPV field.
See you in Athens in October 2026! Our News and Updates section will continue to follow IPVC 2026, bringing readers conference highlights, emerging scientific findings, and new developments in global HPV research.
